Development of Novel Therapeutic Targets for MYC-Related Refractory Diffuse Large B-Cell Lymphoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08429
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Kyushu University
• Principal Investigator: Miyawaki Kohta 九州大学, 大学病院, 助教 (50774709)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: びまん性大細胞型B細胞リンパ腫 / DLBCL / MYC / MYC関連DLBCL / 分子標的薬

Outline of Final Research Achievements

Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma, with a mortality rate of approximately 50%. Among these, MYC-related DLBCL is particularly difficult to treat. This study aimed to develop new therapeutic strategies for MYC-related DLBCL. Through comprehensive gene expression analysis of numerous patient samples, we identified metabolic-related molecules highly expressed in patients with poor clinical prognosis and found that their expression is regulated by MYC. Furthermore, we confirmed that targeting these molecules showed significant therapeutic effects in both in vitro and in vivo models. This study demonstrates the efficacy of a new targeted therapy for MYC-related DLBCL, providing a potential new treatment option for this challenging subtype.

Free Research Field

造血器悪性腫瘍

Academic Significance and Societal Importance of the Research Achievements

びまん性大細胞型B細胞リンパ腫（DLBCL）は最も頻度の高い悪性リンパ腫であり、我々はその中でも特に予後が厳しいMYC関連DLBCLに焦点を当て、新たな治療戦略を創出することを目指した。本研究ではMYC関連DLBCLに対する新たな治療標的を同定するとともに、その有効性と治療の実現可能性を高める重要な知見を提供したものであり、今後の治療法開発に大きく寄与することが期待される。